Related Experiment Video
Updated: Sep 18, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Safety and efficacy of routine anticoagulation after primary PCI in STEMI: a systematic review and meta-analysis
Anika Chowdhury1, Dhruvkumar Arvindbhai Vasoya2, Mahfuja Jahan Ima3
1Shaheed Suhrawardy Medical College and Hospital, Dhaka, 1207, Bangladesh.
Insights
Postprocedural anticoagulation (PPAC) after percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) did not reduce mortality or major adverse cardiovascular events. However, PPAC significantly increased the risk of bleeding events.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Percutaneous coronary intervention (PCI) is a key treatment for ST-elevation myocardial infarction (STEMI).
- The role and effectiveness of postprocedural anticoagulation (PPAC) following PCI in STEMI patients remain debated.
- This study evaluates the clinical outcomes associated with PPAC in STEMI patients undergoing PCI.
Purpose of the Study:
- To assess the necessity and efficacy of postprocedural anticoagulation (PPAC) in STEMI patients after percutaneous coronary intervention (PCI).
- To compare clinical outcomes, including mortality and adverse events, between PPAC and control groups.
Main Methods:
- A systematic literature search was conducted across Embase, PubMed, and Clinicaltrials for relevant randomized controlled trials (RCTs).
- Meta-analysis was performed using RevMan 5.4.1 with a random-effects model, calculating odds ratios (ORs) and 95% confidence intervals (CIs).
- Risk of bias was assessed using Cochrane's RoB 2.0 tool.
Main Results:
- The meta-analysis included 5 RCTs with 13,586 patients; 50.26% received PPAC.
- PPAC did not significantly reduce all-cause mortality (OR 1.08), cardiovascular mortality (OR 1.08), MACE (OR 1.13), stent thrombosis (OR 1.07), or stroke (OR 1.50).
- PPAC was associated with a significantly higher odds of bleeding (OR 1.78; P=0.03).
Conclusions:
- Postprocedural anticoagulation (PPAC) following PCI for STEMI does not offer significant benefits in reducing mortality, MACE, stent thrombosis, or stroke.
- PPAC is associated with an increased risk of bleeding complications.
- Further RCTs are recommended to confirm these findings and guide clinical practice regarding PPAC in STEMI patients.
Abstract:
Percutaneous Coronary Intervention (PCI) is a widely used minimally invasive procedure that restores blood flow to the coronary artery, improving survival in STEMI patients. Despite its widespread application in clinical settings, the necessity and efficacy of postprocedural anticoagulation (PPAC) remain contentious. Our study aims to assess the outcomes of PPAC in STEMI patients who have undergone PCI. A comprehensive search of Embase, PubMed, and Clinicaltrials was conducted to identify randomized controlled trials (RCTs) comparing the clinical outcomes between PPAC and control (placebo or no PPAC) for STEMI after primary PCI. Statistical analyses were performed using RevMan version 5.4.1, employing a random-effects model to calculate odds ratios (ORs) and their 95% confidence intervals (CIs). Risk of Bias Assessment of the articles was assessed using RoB 2.0 software by the Cochrane Collaboration. A total of 5 RCTs comprising 13,586 patients were included, of which 6,829 patients (50.26%) received PPAC. Compared to the non-PPAC group, PPAC did not significantly reduce all-cause mortality (OR 1.08; 95% CI 0.84-1.39; P = 0.54, I2 = 0%), cardiovascular mortality (OR 1.08; 95% CI 0.83-1.39; P = 0.57, I2 = 0%), and MACE (major adverse cardiovascular events) (OR 1.13; 95% CI 0.92-1.37; P = 0.25, I2 = 22%). Additionally, the odds of stent thrombosis (OR 1.07; 95% CI 0.77-1.47; P = 0.69, I2 = 0%) and stroke (OR 1.50; 95% CI 0.49-4.57; P = 0.48, I2 = 58%) did not differ significantly between the groups. However, PPAC was associated with higher odds of bleeding (OR 1.78; 95% CI 1.07-2.97; P = 0.03, I2 = 94%). This meta-analysis reveals no significant differences in the odds of all-cause mortality, cardiovascular mortality, stent thrombosis, and stroke between PPAC and control following PCI for the management of STEMI. However, PPAC was associated with higher odds of bleeding. Further randomized controlled trials are warranted to corroborate these findings.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome I: Introduction
Coronary Artery Disease V: Interprofessional Care

